Varicella zoster immunization

Children less than 12 years of age will have a 97% seroconversion rate following a single vaccination. Adolescents and adults more than 13 years old will only have 78% seroconversion after a single inoculation, but will have 99% conversion after the second vaccination administered 4 to 8 weeks after the first. Antibody titers appear to persist for at least 20 years following immunization. Despite excellent seroconversion rates, breakthrough chickenpox is reported at a rate of 1 case per 10,000 doses distributed. Most cases occurred within the first year following vaccination, and were due to wild-type varicella zoster virus. The majority of breakthrough cases were mild and of short duration.12... 

Varicella vaccine should be administered after 12 months of age and a second dose at 4 years of age. Adolescents and adults without evidence of immunity to varicella zoster should receive two doses of varicella vaccine given 4 to 8 weeks apart. Varicella vaccine is available as a single-component vaccine or in combination with measles, mumps, and rubella vaccine. 

Varicella-zoster immune globulin, five vials (1.25 mL each) intramuscularly administered ideally within 48 hours of exposure but <96 hours (AIM)... 

Irwin, M. et al., Cellular immunity to varicella-zoster virus in patients with major depression, J. Infect. Dis., 178 Suppl 1, S104, 1998. 

Shingles (Varicella). Shingles or varicella is a painful rash condition that often occurs on the torso. It is caused by reactivation of a latent virus called varicella zoster, which is a member of the herpes virus family. After the initial childhood infection, the virus can remain dormant in the nerve trunk for many years and become reactivated when the immune system is compromised. 

Herpes Zoster (Shingles) Zostavax is a live attenuated varicella-zoster virus (VZV) vaccine for the prevention of herpes zoster in individuals 60 years or older. It is supplied in frozen lyophilized form and reconstituted before vaccination. The vaccine boosts VZV-specific immunity and protects individuals against zosters and its complications. 

Polyspecific Response Associated with CNS Autoimmune Diseases. The oligoclonal, intrathecally synthesized IgG contains numerous specific antibodies and autoantibodies. Antibodies are frequently found with specificities against measles, the rubella virus and the varicella-zoster virus, but seldom against the herpes simplex virus. The occurrence of one, two, or three of these antibodies is referred to as the MRZ reaction. The corresponding antigens are not present in these cases. The MRZ reaction is typical of multiple sclerosis as well as cerebral lupus erythematosus and is a chronically evolving immune process (F5, KIO, S16). 

Varicella zoster vaccines Live attenuated strain of herpes virus varicellae Active immunization against chicken pox... 

Temporarily discontinue therapy and expect to treat the patient with varicella-zoster immune globulin, as prescribed, if the patient experiences significant exposure to varicella virus during treatment... 

Varicella Varicella-zoster immune globulin Weight (kg) Dose (units) Postexposure prophylaxis (preferably within 48 hours but no later than within 96 hours after... 

Antiviral Efficacy and Clinical Use. Foscarnet (Fos-cavir) is primarily given to treat CMV retinitis in patients with AIDS.6,24 This agent may also help control other infections in patients with a compromised immune system, including serious cytomegaloviral infections (pneumonia, gastrointestinal infections) and some herpesvirus infections (herpes simplex, varicella-zoster). 

Varicella Varicella-zoster immune globulin Weight (kg) Dose (units) M0 125 IM 10.1- 20 250 IM 20.1- 30 375 IM 30.1- 40 500 IM > 40 625 IM Postexposure prophylaxis (preferably within 48 hours but no later than within 96 hours after exposure) in susceptible immunocomprised hosts, selected pregnant women, and perinatally exposed newborns. 

Immuno globulins (IG) pertusssis IG, rabies IG, tetanus IG, hepatitis B IG, varicella zoster IG, rho(D) IG, normal immune globulin, lymphocyte anti-thymocyte, IB (equine)... 

Trimethoprirtr-sulfamethoxazole one doublestrenglh tablet orally once daily (All) Azithromycin 1,200 mg orally once weekly (AQ or darithromydn 500 mg orally twice daily (AO Varicella-zoster immune globulin, five vials (1 25 ml each) intramuscularly administered ideally within 48 hours of etposure but 96 hours (Alll)... 

Varicella-Zoster Immunization. Immunization against varicella was approved in the United States in 1995 and is administered to children 12 to 18 months of age or older if they have not had chickenpox. It has been shown to be most effective in the year after vaccination however, breakthrough disease was noted but foimd to be mild. Varicella vaccination reduces the number of related deaths, especially in children aged 1 to 4 years,... 

Impaired immune responses render the subject more liable to bacterial and viral infections. Treat all infection early and vigorously (using bactericidal drugs where practicable) use human gamma globulin to protect if there is exposure to virus infections, e.g. measles, varicella. For example, patients who have not had chickenpox and are receiving therapeutic (as opposed to replacement) doses of corticosteroid are at risk of severe chickenpox they should receive varicella-zoster immunoglobulin if there has been contact with the disease within the previous 3 months. 

Viral infections contracted during steroid therapy can be overwhelming because the immune response of the body may be largely suppressed. This is particularly relevant to immunosuppressed patients exposed to varicella/herpes zoster virus, which may cause fulminant illness they may need passive protection with varicella/zoster immimoglobulin, VZIG, as soon as practicable. Continuous use of prednisolone 20 mg/day (or the equivalent) is immunosuppressive. But a corticosteroid may sometimes be useful in therapy after the disease has begun (thyroiditis, encephalitis) and there has been time for the immune response to occur. It then acts by suppressing unwanted effects of immime responses and excessive inflammatory reaction. 

Oka strain Varicella vaccine (Merck) has been evaluated in immunocompromised children with leukemia in remission (6,7). Most children had chemotherapy stopped 1 week before and 1 week after immunization glucocorticoids were also stopped for 3 weeks (from 1 week before to 2 weeks after immunization). Varicella vaccine was safe, immunogenic, and effective in leukemic children at risk of serious disease or death from chickenpox. The major adverse effect was a mild rash in 50% of the children within 1 month of immunization, about 40% of whom were treated with aciclovir. A mild form of Varicella developed in 14% of immunized children exposed to Varicella (household contacts). The vaccine protected completely against severe Varicella. Leukemic vaccinees were less likely to develop zoster than were comparable children with leukemia who had wild tjrpe Varicella. 

A 19-month-old girl was immunized against Varicella at 15 months of age and later developed zoster infection (18). Viral cultures from various lesions isolated Varicella zoster virus. The Oka vaccine strain was revealed by polymerase chain reaction. 

The authors felt that this case mandated a careful review of all cases of zoster after Varicella immunization. Zoster induced by Varicella immunization could have implications for the use of immunization to prevent zoster in the elderly, a population with almost uniform Varicella zoster latent virus and at higher risk of zoster. 

A 5-year-old boy developed zoster-like vesicular lesions 4 years after Varicella immunization. Virological examination showed Herpes simplex virus type 1, and so the vesicnlar lesions could not be attributed to the Varicella zoster virus vaccine strain, demonstrating the difficulty in confirming causality between time-related events (22). 

Kohl S, Rapp J, La Russa P, Gershon AA, Steinberg SP. Natural Varicella-zoster virus reactivation shortly after varicella immunization in a child. Pediatr Infect Dis J 1999 18(12) 1112-13. 

Ocular antiviral chemotherapy in the horse is adapted from that used in herpes simplex virus (HSV) and varicella zoster keratitis in humans. The agents used are nucleotide analogs capable of inhibiting viral replication by competitive inhibition of the uptake of the nucleotide into the viral genome. These agents are virustatic and require an intact immune system to suppress or eliminate the virus from the eye. They probably do not eradicate any latent infection. The antiviral drugs available currently do not penetrate intact comeal epithelium and are poorly disseminated within the comeal stroma. The availability of these dmgs will vary in different countries and some may only be obtained from hospital pharmacies. 

Adults who ore exposed tii chickenpox. should continue to receive varicella-zoster immune globulin (VZIG). 

Varicella-zoster virus (VZV) Enveloped, isocahedral particles 1 50 nm in diameter Causes chickenpox in children virus remains dormant in any dorsal root ganglion of the CNS release of immune control in the elderly stimulates reactivation resulting in shingles... 

Grose, C. and Brunei, P. A. (1978) Varicella-zoster virus isolation and propagation in human melanoma cells at 36 and 32 degrees C. Infect. Immun. 19, 199-203. 

Impaired cell-mediated immunity Lymphoma Immunosuppressive therapy (steroids, cyclosporine, chemotherapy) Bacteria Listeria, Nocardia, Legionella, Mycobacteria Fungi Cryptococcus neoformans, Candida, Aspergillus, Histoplasma capsulatum Viruses Cytomegalovirus, varicella-zoster, herpes simplex Protozoal Pneumocystis jiroveci... 

Varicella is a highly contagious disease caused by varicella-zoster virus. The clinical illness is characterized by the appearance of successive waves of pruritic vesicles that rapidly crust over. Malaise and fever are common and last for 2 to 3 days. The virus remains dormant in the dorsal ganglia and reactivates as herpes zoster, also known as shingles. Although the exact stimulus for reactivation is unknown, a decrease in varicella-specific cell-mediated immunity associated with age or immunosuppression appears to be necessary but not sufficient for reactivation. 

Varicella zoster virus (VZV) Significant exposure to chickenpox or shingles for patients who have no history of either condition or, if available, negative antibody to VZV Varicella zoster immune globulin (VZIG), 5 vials (1.25 mL each) intramuscularly administered ideally within 48 h of exposure but <96 h... 

VS VSD vss VT v tach VTE VTX W V V v/v VVFR VVOR VW VWM VZ VZIG VZV vital signs versus venous stasis retinopathy vital signs stable ventricular tachycardia tidal volume ventricular tachycardia venous thromboembolism vertex varicose veins vulva and vagina volume to volume ratio vesicovaginal fistula repair visual-vestibulo-ocular-reflex vessel wall ventricular wall motion varicella zoster varicella zoster immune globulin varicella zoster virus... 

Vaccinia immune globulin IV is a vaccinia-specific immunoglobulin G (IgG), which directly neutralizes vaccinia virus. It is indicated in treatment and/or modification of aberrant infections induced by vaccinia virus (including accidental implantation in eyes, mouth, or other areas where vaccinia infection would constitute a special hazard), eczema vaccinatum, progressive vaccinia, severe generalized vaccinia, and vaccinia infections in individuals who have skin conditions such as bums, impetigo, varicella-zoster, or poison ivy, or in individuals with eczematous skin lesions. Treat complications that include vaccinia keratitis with caution. 

---